ALLO - Allogene Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.58
+0.39 (+1.38%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close28.19
Open28.47
Bid24.51 x 1000
Ask32.80 x 1200
Day's Range28.00 - 28.78
52 Week Range21.67 - 35.55
Volume323,145
Avg. Volume573,168
Market Cap3.472B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.67
Trade prices are not sourced from all markets
  • KPMG's former S.F. head Debbie Messemer lands on leading fintech's board
    American City Business Journals2 days ago

    KPMG's former S.F. head Debbie Messemer lands on leading fintech's board

    Messemer's expertise in working with clients in banking and finance and grappling with rapid change will be useful in her board service.

  • East Bay accounting firm’s new leader says improv upped his presentation skills
    American City Business Journals3 days ago

    East Bay accounting firm’s new leader says improv upped his presentation skills

    The new leader discusses staffing and recruiting in the pricey Bay Area as well as his favorite rock bands and the benefits he gets from performing in his own improv troop, Butter Boost.

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Novavax and Allogene Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...

  • Cell therapy pioneer eyes Bay Area manufacturing
    American City Business Journals11 days ago

    Cell therapy pioneer eyes Bay Area manufacturing

    The South San Francisco company, which has quickly grown to 105 employees and raised more than a half-billion dollars, plans to site a cell manufacturing facility in the Bay Area.

  • American City Business Journals18 days ago

    Here are the winners and losers from Bay Area's IPO class of 2018

    Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.

  • GlobeNewswirelast month

    Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 1:30 p.m. Pacific Time. A live audio webcast of the presentation will be available on the Investors section of Allogene’s website, www.allogene.com. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.

  • Cambridge's Moderna sets record with $604M IPO
    American City Business Journalslast month

    Cambridge's Moderna sets record with $604M IPO

    The Cambridge biotech shattered records on Thursday night when it announced it had raised more than $604 million in an IPO, the largest ever in the sector.

  • Here's how Moderna's IPO stacks up against others in biotech
    American City Business Journalslast month

    Here's how Moderna's IPO stacks up against others in biotech

    It'll just be the latest in the biotech industry's increasingly high-priced market launches.

  • GlobeNewswire2 months ago

    Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

    The findings demonstrate the potential of ALLO-715 as a novel AlloCAR T therapy for multiple myeloma and other BCMA-positive malignancies. The data were presented today by Cesar Sommer, Ph.D., Principal Scientist at Allogene, in an oral session at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. “Based on these promising preclinical data, we plan to submit an Investigational New Drug (IND) application for ALLO-715 and initiate a Phase 1 clinical trial in 2019 in relapsed or refractory multiple myeloma,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.

  • Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech
    Investor's Business Daily2 months ago

    Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech

    The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.

  • Here's how much better insiders have profited from this year's IPO boom
    American City Business Journals2 months ago

    Here's how much better insiders have profited from this year's IPO boom

    If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.

  • GlobeNewswire2 months ago

    Allogene Therapeutics Announces November 2018 Investor Conference Schedule

    Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor conferences in November 2018. A live audio webcast of each event will be available on the Investors section of Allogene’s website, www.allogene.com. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.

  • Business Wire3 months ago

    Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

    SOUTH SAN FRANCISCO, Calif.-- -- Data Provide Insights in Preparation for Investigational New Drug Submissions Planned in 2019 for ALLO-501 in Non-Hodgkin Lymphoma and ALLO-715 in Multiple Myeloma Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced that it will present data supporting its allogeneic ...

  • Strong IPO pace continued in October but some cracks are showing
    American City Business Journals3 months ago

    Strong IPO pace continued in October but some cracks are showing

    Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.

  • ACCESSWIRE3 months ago

    How This Underfollowed $6 Biotech Could Be Worth $10

    The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.

  • GuruFocus.com3 months ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week from the following companies: Allogene Therapeutics, Conagra Brands, Texas Capital Bancshares, Fastenal and CymaBay Therapeutics

  • GuruFocus.com3 months ago

    Allogene Therapeutics Inc (ALLO) President and CEO David D Chang Bought $720,000 of Shares

    President and CEO of Allogene Therapeutics Inc (NASDAQ:ALLO) David D Chang bought 40,000 shares of ALLO on 10/15/2018 at an average price of $18 a share.

  • Business Wire3 months ago

    Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a ...

  • Benzinga3 months ago

    Allogene's IPO: What You Need To Know

    Allogene Therapeutics is set to begin trading on the Nasdaq Stock Exchange under the ticker symbol “ALLO.” The stock is expected to debut Thursday, Oct. 11, although an official IPO date has not yet been ...